How Much Dividend Does CymaBay Therapeutics Inc. (CBAY) Pay?

0
57

CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded with an addition of $0.37 to close at $5.91 on Thursday, an upside of 6.68 percent. An average of 970,732 shares of common stock have been traded in the last five days. There was a gain of $0.89 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 866,313 shares traded, while the 50-day average volume stands at 523,659.

CBAY stock has increased by 67.88% in the last month. The company shares reached their 1-month lowest point of $3.23 on 11/30/22. With the stock rallying to its 52-week high on 12/29/22, shares of the company touched a low of $1.67 and a high of $5.63 in 52 weeks. It has reached a new high 15 times so far this year and achieved 63.91% or $2.47 in price. In spite of this, the price is up 4.97% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

CymaBay Therapeutics Inc. (CBAY) stock’s beta is 0.32. Other valuation ratios to consider include the price-to-book (PB) ratio at 8.03.

Financial Health

The quick ratio of CymaBay Therapeutics Inc. for the three months ended June 29 was 12.20, and the current ratio was 12.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.43 and a total debt to equity ratio of 1.43 for the quarter ending June 29. Its gross profit as reported stood at $87.58 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CymaBay Therapeutics Inc.’s return on assets was -57.30%.

Earnings Surprise

For the three-month period that ended June 29, CymaBay Therapeutics Inc. had $122.72 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$24.51 million in the quarter, while revenues were grew 7.47%. The analyst consensus anticipated CymaBay Therapeutics Inc.’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.31, a -3.30% surprise. For the quarter, EBITDA amounted to -$21.21 million. Shareholders own equity worth $84.68 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at CymaBay Therapeutics Inc. (CBAY) price momentum. RSI 9-day as of the close on 28 December was 90.22%, suggesting the stock is Overbought, with historical volatility in this time frame at 56.34%.

As of today, CBAY’s price is $5.48 +17.94% or $0.89 from its 5-day moving average. CBAY is currently trading +73.08% higher than its 20-day SMA and +45.16% higher than its 100-day SMA. However, the stock’s current price level is +72.57% above the SMA50 and +96.97% above the SMA200.

The stochastic %K and %D were 96.94% and 96.78%, respectively, and the average true range (ATR) was 0.30. With the 14-day stochastic at 99.25% and the average true range at 0.27, the RSI (14) stands at 85.51%. The stock has reached 0.52 on the 9-day MACD Oscillator while the 14-day reading was at 0.89.

Analyst Ratings

The consensus rating for CymaBay Therapeutics Inc. (CBAY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CBAY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 9 others rate it as a “buy”.

What is CBAY’s price target for the next 12 months?

Analysts predict a range of price targets between $8.00 and $14.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for CymaBay Therapeutics Inc. (CBAY) stock is $10.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here